Auransa Inc.

Auransa Inc. operates as a clinical-stage biopharmaceutical company, utilizing AI technology to discover innovative therapeutics, primarily focused on oncology and cancer care solutions. Founded in 2014, Auransa Inc. is based in Palo Alto, US, where it specializes in developing precision medicine approaches informed by comprehensive human disease data.

The company has undergone no significant pivots since its inception. Pek Lum serves as both the Founder and CEO, leading the company through its growth and operational strategies. Auransa has successfully raised USD 14. 14 mn in a Series A funding round in May 2017, which constitutes the total amount raised to date, and currently holds a valuation of USD 70.

369 mn. Auransa is a clinical-stage biopharmaceutical company that leverages an advanced AI platform to identify novel therapeutics, particularly in the field of oncology. The core offerings revolve around proprietary technology that integrates vast amounts of human disease data to develop precision medicine approaches aimed at improving cancer care. The platform has processed over 500,000 gene expression profiles, enabling the advancement of specific therapies, including investigational treatments for liver cancer and heart-safe chemotherapy.

Products target healthcare providers and institutions within the biotechnology and pharmaceutical sectors, with clinical trials currently active in Asia, marked by the recent administration of AU409 to the first patient in the region. Auransa's revenue model is centered around partnerships and collaborations with healthcare organizations and research institutions, focusing on B2B transactions. They monetize their AI platform and therapeutic developments through licensing agreements and collaborative research, involving milestone payments related to clinical trial progress and potential commercialization of therapies. Specific pricing plans for services and products remain undisclosed, but transactions typically include fees for access to proprietary technology and ongoing R&D support, with key products like AU409 central to their revenue strategy.

Auransa plans to leverage its recent funding of USD 14. 14 mn from May 2017 to expand its product offerings and enter new geographical markets. The company is designing new therapeutics with the aim of launching them in the coming years, while also focusing on expanding its clinical trials in Asia and potentially other global markets. This funding will support the advancement of therapeutic candidates through further research and development, driving the company's growth strategies.